{"entity":{"id":"ctong-2508","kind":"trial","name":"CTONG 2508 (ADAPT Lung)","aka":["ADAPT Lung","CTONG2508"],"tldr":"A Chinese lung cancer trial that uses blood tests for leftover cancer to decide how much immunotherapy to give after surgery.","summary":"CTONG 2508, ADAPT Lung (NCT07120698), is a single-arm phase 2 trial of residual disease-guided adjuvant sintilimab in patients with stage II to IIIB non-small cell lung cancer who did not achieve a pathological complete response after neoadjuvant immunotherapy with chemotherapy, at the Third People's Hospital of Chengdu and Guangdong Provincial People's Hospital. The primary endpoint is two-year event-free survival; primary completion is estimated for June 2029.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07120698","url":"https://clinicaltrials.gov/study/NCT07120698"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["mrd-testing","checkpoint-inhibitor"],"targets":[],"drugs":["sintilimab"],"companies":["ctong"],"institutions":["guangdong-provincial-peoples-hospital"],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07120698","phase":"2","setting":"Stage II to IIIB non-small cell lung cancer without pathological complete response after neoadjuvant immunotherapy plus chemotherapy: adjuvant sintilimab adapted to residual disease results","sponsor":"Guangdong Association of Clinical Trials","started":"2025-11-05","startedType":"actual","enrolled":115,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/ctong-2508/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"company":[{"id":"ctong","kind":"company","name":"Chinese Thoracic Oncology Group","route":"/companies/ctong/"}],"institution":[{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}]}}